fluoromisonidazole has been researched along with Rhabdomyosarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubois, L; Eriksson, J; Lambin, P; Lieuwes, NG; Peeters, SG; van Dongen, GA; van Elmpt, W; Zegers, CM | 1 |
| Bol, A; Bormans, G; Cloetens, L; Dubois, L; Grégoire, V; Haustermans, K; Labar, D; Landuyt, W; Mortelmans, L; Nuyts, J | 1 |
| Bormans, G; Dubois, L; Dupont, P; Flamen, P; Haustermans, K; Landuyt, W; Mortelmans, L; Verbeken, E; Vermaelen, P | 1 |
3 other study(ies) available for fluoromisonidazole and Rhabdomyosarcoma
| Article | Year |
|---|---|
A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Computer Simulation; Imidazoles; Misonidazole; Models, Biological; Nitroimidazoles; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Reproducibility of Results; Rhabdomyosarcoma; Sensitivity and Specificity; Triazoles | 2015 |
[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
Topics: Animals; Autoradiography; Biomarkers; Heart; Hypoxia; Male; Misonidazole; Myocardium; Nitroimidazoles; Positron-Emission Tomography; Rats; Reference Values; Rhabdomyosarcoma; Tissue Distribution | 2009 |
Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.
Topics: Animals; Antibodies, Monoclonal; Carbonic Anhydrase III; Cell Hypoxia; Fluorodeoxyglucose F18; Heart; Immunoenzyme Techniques; Lung; Male; Misonidazole; Muscles; Nitroimidazoles; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Rats; Rhabdomyosarcoma | 2004 |